Arki Pharmaceuticals

Arki Pharmaceuticals is a longevity-focused biotechnology company dedicated to mitigating the harmful effects of Advanced Glycation End-products (AGEs) and methylglyoxal (MG). Spun out of the Buck Institute for Research on Aging, the company utilizes a precision nutrition and therapeutic approach to combat metabolic dysfunction and age-related diseases. Their lead commercial product, GLYLO, is a first-in-class supplement designed to reduce glycation, manage weight, and promote healthy aging. Beyond its consumer health offerings, Arki is advancing a pipeline of small molecule therapeutics targeting the glyoxalase system to treat diabetic complications and other metabolic disorders. The company's research is rooted in the biology of detoxification pathways that naturally decline with age.